As you are aware the EU Clinical Trials Directive is set to become part of the UK’s regulatory and legal landscape from 1 May, 2004. Richmond Pharmacology has welcomed the directive which will help to harmonise trial standards across the board.We support the MHRA (Medicines and Healthcare products Regulatory Agency) which regulates implementation of the Directive, and we applaud our industry partners who have ensured that the implementation does not slow down or hinder the competitiveness of the UK’s clinical research industry.We have put together a guide on the EU Directive following numerous client requests for more information and greater clarity on how the directive will impact on research projects, timelines and approval systemsTo request a copy of the guide please email a.hurd@richmondpharmacology.com

Latest news

Richmond Pharmacology Appoints Patrick Ramiah as Director of Clinical Project Delivery & Operational Excellence

September 1, 2025
Richmond Pharmacology is delighted to announce the promotion of Patrick Ramiah to the role of Director of Clinical Project Delivery & Operational Excellence, effective from 1 September 2025.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event